Phase I study of XL119 [becatecarin] in patients with relapsed or refractory acute myeloid leukemia, myelodysplastic syndromes, acute lymphocytic leukemia, or chronic myeloid leukemia in blastic-phase

Trial Profile

Phase I study of XL119 [becatecarin] in patients with relapsed or refractory acute myeloid leukemia, myelodysplastic syndromes, acute lymphocytic leukemia, or chronic myeloid leukemia in blastic-phase

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Becatecarin (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 06 Aug 2007 Status changed from recruiting to completed.
    • 22 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top